Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Clinical trial

Dexmedetomidine as an Adjuvant to Local Anesthesia in Supraclavicular Plexus Block, A Randomized Control Trial.

ID
Name
F.Med.25th August/2020/10
Description
In this study, we will assess the effect of combined Dexmedetomidine and Bupivacaine analgesia on the onset and duration of anesthesia in supraclavicular plexus block compared to Bupivacaine alone.
Trial arms
Trial start
2020-10-01
Estimated PCD
2024-08-01
Trial end
2024-08-01
Status
Recruiting
Treatment
Dexmedetomidine
Highly selective α2-adrenergic receptor agonist. With sedative, analgesic, peri-operative sympatholytic and hemodynamic stabilizing properties.
Arms:
Dexmedetomidine and Bupivacaine
Other names:
non
Size
70
Primary endpoint
The onset of anaesthesia in supraclavicular plexus block
"up to 9 hours"
The duration of anesthesia in supraclavicular plexus block
"up to 9 hours"
Eligibility criteria
Inclusion Criteria: * Aged between 18-75 years. * Classified as grades 1 or 2 by the American Society of Anesthesiology Classification of .physical status. * Willing and able to sign a consent form. Exclusion Criteria: * Patients under the following conditions will be excluded: Known hypersensitivity to Bupivacaine, Dexmedetomidine, and local anesthetics. * Uncontrolled diabetes mellitus. * Peripheral neuropathy. * SevereCoagulopathy. * Infection at the site of block. * Pregnancy. * Cardiac arrhythmias. * Prescription of beta blockers. * Psychological disorders.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'OTHER', 'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['PARTICIPANT']}}, 'enrollmentInfo': {'count': 70, 'type': 'ESTIMATED'}}
Updated at
2023-07-20

1 organization

1 product

1 indication

Organization
Zaher Nazzal
Product
Dexmedetomidine
Indication
Supraclavicular Brachial Plexus Block